Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuation

INTRODUCTION: Natalizumab (NTZ) is an effective drug for the treatment of relapsing‐remitting multiple sclerosis. In some patients discontinuation is mandatory due to the risk of progressive multifocal leukoencephalopathy. However, severe clinical and radiological worsening has been described after...

Descripción completa

Detalles Bibliográficos
Autores principales: González‐Suarez, Inés, Rodríguez de Antonio, Luis, Orviz, Aida, Moreno‐García, Sara, Valle‐Arcos, María D., Matias‐Guiu, Jordi A., Valencia, Cristina, Jorquera Moya, Manuela, Oreja‐Guevara, Celia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5390845/
https://www.ncbi.nlm.nih.gov/pubmed/28413713
http://dx.doi.org/10.1002/brb3.671

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5390845/
https://www.ncbi.nlm.nih.gov/pubmed/28413713
http://dx.doi.org/10.1002/brb3.671

Ejemplares similares